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Abstract
Aims: Pulmonary veno-occlusive disease (PVOD) is a rare condition of pulmonary
arterial hypertension (PAH), in which post-capillary veins are affected. Since the
therapeutic approach in PVOD differs from other forms of PAH, it is crucial to
establish the diagnosis. Due to the fact that affected patients are often
hemodynamically unstable, minimal invasive procedures are necessary for the
diagnostic work-up. Chronic alveolar haemorrhage has been observed during
bronchoalveolar lavage in PVOD cases. This study therefore investigates whether
signs of alveolar haemorrhage can also be found in the sputum of these patients.
Methods and Results: Six patients suffering from PVOD were included in this
analysis. As controls, patients with idiopathic PAH (n511), chronic thromboembolic
PH (n59) and with sclerodermia-associated PH (n510) were assessed. Sputum
from every patient was obtained by a non-invasive manner. The amount of
haemosiderin-laden macrophages was determined using the Golde score. There
were statistically significant more haemosiderin-laden macrophages in the sputum of
patients suffering from PVOD as compared to the other groups (P,0.05). Assuming
a cut-off of 200 on the Golde score, all of the 6 PVOD patients surpassed this value
compared with only 1 out of the 30 cases with precapillary PH. Thus, sensitivity and
specificity with respect to the diagnosis of PVOD was 100% and 97%, respectively.
Conclusion: The content of haemosiderin-laden macrophages in the sputum of
patients suffering from PVOD is significantly higher as compared to other forms of
PH and may be useful in the non-invasive diagnostic work-up of these patients.
OPEN ACCESS
Citation: Lederer H, Muggli B, Speich R, Treder U,
Stricker H, et al. (2014) Haemosiderin-Laden
Sputum Macrophages for Diagnosis in Pulmonary
Veno-Occlusive Disease. PLoS ONE 9(12):
e115219. doi:10.1371/journal.pone.0115219
Editor: James West, Vanderbilt University Medical
Center, United States of America
Received: August 20, 2014
Accepted: November 20, 2014
Published: December 12, 2014
Copyright:  2014 Lederer et al. This is an open-
access article distributed under the terms of the
Creative Commons Attribution License, which
permits unrestricted use, distribution, and repro-
duction in any medium, provided the original author
and source are credited.
Data Availability: The authors confirm that all data
underlying the findings are fully available without
restriction. All relevant data are within the paper.
Funding: Dr. Breitenstein received educational
funding from Actelion Switzerland. The funders had
no role in study design, data collection and
analysis, decision to publish, or preparation of the
manuscript.
Competing Interests: Dr. Breitenstein received
educational funding from Actelion Switzerland. This
does not alter the authors’ adherence to PLOS
policies on data sharing and materials.
PLOS ONE | DOI:10.1371/journal.pone.0115219 December 12, 2014 1 / 10
Introduction
Pulmonary hypertension (PH) is a severe condition characterized by elevated
mean pulmonary arterial pressure $25 mmHg resulting in right heart failure and
death [1]. According to recent guidelines, PH can be classified based on clinical
and haemodynamic criteria. One distinct subgroup of pulmonary arterial
hypertension (PAH) is pulmonary veno-occlusive disease (PVOD) [2, 3], which
accounts for only 5–10% of all cases of PAH [4]. In contrast to the involvement of
small pre-capillary pulmonary arteries as in PAH, vascular pathology in PVOD is
characterized by fibrous remodeling of post-capillary septal veins and praeseptal
venules [5, 6].
Clinical presentation of PVOD is non-specific and very similar to PAH. Hence,
distinguishing PVOD from PAH based on clinical criteria is often difficult.
Nevertheless, since PVOD has a worse prognosis than the various forms of PAH
and may exhibit a poor and even adverse response to common vasodilator
therapies which may lead to severe and sometimes fatal pulmonary oedema, it is
of crucial importance to identify cases of PVOD. In addition, a diagnosis of
PVOD has serious therapeutic consequences since such patient qualify for lung
transplantation and should be listed as soon as possible.
PVOD can be suspected by the constellation of significant hypoxaemia, a very
low carbon monoxide diffusion capacity (DLCO) as well as characteristic
radiological features on chest computed tomography [7–9]. The definitive
diagnosis of PVOD would require surgical lung biopsy, but such an invasive
approach is not feasible in these high-risk patients. Hence, less invasive diagnostic
tools would be helpful. As mentioned, PVOD affects the post-capillary veins and
may hence result in engorgement of the capillaries leading to occult alveolar
haemorrhage. Indeed, a study of bronchoalveolar lavage (BAL) in patients
suffering from PVOD could demonstrate a significantly higher percentage of
haemosiderin-laden macrophages as compared to other form of PH [10]. Hence,
BAL has become an additional investigation tool to diagnose PVOD. Nevertheless,
even though BAL has been reported to be a safe intervention in stable PH patients
[10], it is an invasive procedure and may carry an increased risk of respiratory
impairment and hemodynamic instability. Thus, there is an urgent need for a less
invasive procedure. The aim of the current study is to investigate whether the
analysis of haemosiderin-laden macrophages in the sputum of patients, might
represent an additional diagnostic tool in the work-up for PVOD comparable to
BAL.
Materials and Methods
Patient data
The study was conducted at the Pulmonary Hypertension Unit, University
Hospital Zurich, Switzerland, between July 2003 and November 2011. PVOD was
assumed with a mean pulmonary arterial pressure of $25 mmHg, a pulmonary
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arterial wedge pressure #15 mmHg and the presence of at least 2 out of 3 chest
computed tomography findings (centrilobular ground-glass opacities, septal lines
and mediastinal lymph node enlargement) [11], as well as laboratory findings
suggestive for PVOD, i.e. a reduced diffusion capacity of the lungs for carbon
monoxide (DLCO; ,50%) and hypoxaemia at rest with a PaO2,8 kPa, and
clinical sings like crackles on auscultation or pulmonary oedema after vasodilator
therapy [8, 9, 12]. Pathological confirmation of PVOD could be obtained in only
one patient from the explanted lungs after lung transplantation.
As control groups, patients suffering from idiopathic PAH (IPAH; n511)
[13, 14], chronic thromboembolic PH (CTEPH; n59) [13–15], and scleroderma-
associated PAH (SPAH; n510) [13, 14, 16] were included in this analysis. The
diagnosis of these entities was established according to current guidelines [13–16].
Ethical approval was granted by the institutional ethical committee
(‘‘Kantonale Ethikkommission Zu¨rich’’). All subjects signed an informed consent
form.
Sputum collection and processing
Sputum from every patient was obtained by a non-invasive manner without any
induction by hypertonic saline solution. Per visit, each patient has given three
probes of sputum which where stained for haemosiderin by the Prussian blue
Table 1. Clinical characteristics of the four patient groups.
Group
IPAH (n511) CTEPH (n59) SAPH (n510) PVOD (n56)
Gender [m/f] 7/4 5/4 0/10 5/1
Age [years] 55¡20 63¡16 67¡10 70¡6
Smoking [%] 36 13 10 33
NYHA functional class [n]
I-II 2/11 4/9 2/10 1/6
III-IV 9/11 5/9 8/10 5/6
Baseline 6-MWD [m] 292¡127 431¡183 359¡160 295¡74
Heart rate [bpm] 77¡10 92¡17 78¡16 82¡13
Systolic blood pressure [mmHg] 117¡17 134¡24 118¡15 119¡20
Diastolic blood pressure [mmHg] 68¡8 74¡14 68¡12 71¡11
Mean pulmonary artery pressure [mmHg] 44¡16 45¡17 32¡12 39¡11
Pulmonary artery wedge pressure [mmHg] 13¡10 11¡7 13¡5 8¡3
Central venous pressure [mmHg] 9¡5 8¡6 7¡5 6¡4
Cardiac index [l/min/m2] 3.6¡1.3 2.6¡0.5 3.1¡1.1 2.8¡0.5
Mixed venous oxygen saturation [%] 65.2¡9.1 62.7¡9.7 73.0¡6.7 60.4¡14.2
Pulmonary vascular resistance [WU] 6.2¡3.1 9.6¡5.6 4.6¡2.9 6.8¡3.5
Systemic vascular resistance [WU] 16.0¡3–6 21.7¡5.9 19.2¡6.0 15.2¡1.7
doi:10.1371/journal.pone.0115219.t001
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procedure. The patients were encouraged as far as possible to produce a viable
sputum sample. However, after 5 attempts the procedure was halted in
consideration of the reduced general condition of these patients. The slides were
stored and then examined by two physicians unaware of the clinical course of the
patients (H.L., B.M.). Quality criteria for sputum was presence of more than 25
macrophages on the slides. The haemosiderin content of alveolar macrophages
was estimated according to the Golde scoring system [17]. Each macrophage was
scored for haemosiderin content using the following scale: 0, no color; 1, faint
blue in a part or the whole cytoplasm without or with single deep blue granules; 2,
medium color intensity throughout the cytoplasm without or with deep blue
granules in minor (,50%) portions of the cytoplasm; 3, deep blue granules in
major (.50%) portions of the cytoplasm; and 4, deep blue granules throughout
the cell (Fig. 1). The total score was extrapolated to an average of 100 cells.
Statistical analysis
Continuous variables are expressed as median (interquartile range) and
frequencies for categorical variables. The Golde score was analyzed by the Kruskal-
Wallis One-Way analysis of variance, the Spearman’s coefficient of correlation was
used to assess inter-observer variation in the analysis of the Golde score. Clinical
data was analyzed by the x2 test for categorical and by the Kruskal-Wallis One-
Way analysis for continuous data. The level of significance was defined as a two-
tailed P value ,0.05. All statistical analyses were performed with SPSS Statistics
19.0 for Windows (SPSS, Inc. 2010).
Fig. 1. Description of the Golde score calculation in sputum macrophages.
doi:10.1371/journal.pone.0115219.g001
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Results
Patient’s characteristics
36 subjects were included in the present study: IPAH (n511), CTEPH (n59),
SAPH (n510), and PVOD (n56). A detailed overview of the patient’s
characteristics is summarized in table 1. Briefly, there was a non-significant trend
towards higher age in the PVODs (70¡6 years in PVOD versus 55¡20 years for
IPAH, 63¡16 years for CTEPH, and 67¡10 years for SAPH, respectively;
Fig. 2. Haemosiderin-laden macrophages are significantly (P,0.05) more present in sputum from
PVOD patients as compared to the others (IPAH, CTEPH and SAPH, respectively).
doi:10.1371/journal.pone.0115219.g002
Fig. 3. Histologic specimen from a patient suffering from PVOD who underwent lung transplantation.
Intimal thickening and fibrous obstruction of septal veins and preseptal venules (asterixis) as well as features
of pulmonary capillary hemangiomatosis with proliferation of dilated and congested capillaries as well as
dilated lymphatic (left upper and right lower part of the figure; arrowhead). Alveoli with haemosiderin-laden
macrophages of Golde score 3–4 (arrow) are clearly visible. Haemosiderin-negativ macrophages are difficult
to be identified. Golde score from the tissue was 304, as compared to 252 in the sputum.
doi:10.1371/journal.pone.0115219.g003
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P5NS), while there was a female predominance in the SAPH group as compared
to the others (100% female in SAPH versus 36.4% for IPAH, 44.4% for CTEPH,
and 20.0% for PVOD; P,0.05). Dyspnea was the main symptom in all patients
with the majority suffering from New York Heart association functional class III-
IV. The 6-minute walking distance (6-MWD) as well as the mean pulmonary
artery pressure and the cardiac index did not differ significantly between the
groups.
In table 2, the clinical features of the 6 patients with suspected PVOD are
shown. All of them demonstrated at least 4 findings characteristically associated
with PVOD from data of the literature, including at least 2 of the radiologic
criteria.
Amount of haemosiderin-laden macrophages is higher in PVOD
as compared to the other forms of precapillary PH
All slides were examined for haemosiderin-laden macrophages by two blinded
physicians unaware of the clinical data. The method to calculate the Golde score is
summarized in Fig. 1. The mean of the evaluable sputum macrophages was 267
(median 263; range 240–315). An interobserver variation between the two
investigators with respect to the number of identifiable sputum cells as well as to
the Golde score could be excluded according to the Spearman’s coefficient of
correlation (r.0.9). There was no difference in the content of haemosiderin-laden
macrophages between IPAH, CTEPH and SPAH (P5NS; Fig. 2). However, there
were statistically significant more haemosiderin-laden macrophages in the sputum
of patients suffering from PVOD demonstrated by a Golde score.200 as
compared to the other groups (P,0.05; Fig. 2). All PVOD patients with evaluable
cells in their sputum had a Golde score .200. Assuming a cut-off value for the
Golde score of 200, the sensitivity for the diagnosis of clinical PVOD was 100%
and the specificity 97%, respectively.
For comparison with BAL, we could retrieve only one sample from patient 1
(which was obtained one year before the sputum). The Golde score at that time
point was 312, i.e. comparable to the count of 264 found in the sputum. Since all
patients except one did not qualify for lung transplantation, we could only assess
one histological specimen. Interestingly, this patient also showed features of
capillary hemangiomatosis (Fig. 3). The Golde score calculated from the tissue
was 304 and hence comparable to the count of 252 found in the sputum.
Discussion
The present analysis demonstrates for the first time that the content of
haemosiderin-laden macrophages in the sputum is significantly higher in patients
suffering from PVOD as compared to other forms of PH. The sensitivity and
specificity for the diagnosis of clinical PVOD was 100% and 97%, respectively.
Hence, sputum examination for haemosiderin-laden macrophages may be
Haemosiderin-Laden Macrophages Are Increased in PVOD
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considered as an additional non-invasive diagnostic piece of puzzle in the work-
up of this serious disease. In addition, our study confirms the previous finding of
Rabiller and colleagues, who could demonstrate comparable findings by
examining alveolar macrophages from BAL [10].
PVOD is a rare cause of PAH accounting for less than 5–10% of all PAH cases
[18]. According to the recent guidelines, PVOD is considered as a subgroup of
PAH [3]. On one side, the clinical presentation resembles that of PAH including
the presence of similar risk factors such as HIV infection. In contrast, the main
pathophysiological difference is the fibrous remodeling of post-capillary septal
veins and praeseptal venules which is not present in other forms of PAH except to
some extent in SPAH [19, 20]. Importantly, the involvement of post-capillary
vessels allows a histological differentiation between the different entities of PH
and also has important implications regarding the therapeutic options.
Particularly the use of intravenous as well as oral vasodilators, which are
commonly used in the treatment of PAH, may be dangerous due to the risk for
development of pulmonary oedema in these patients suffering from PVOD [8, 20–
23]. Therefore, to establish the correct diagnosis is crucial to offer optimal
treatment for these patients.
Since lung biopsy is usually not possible in PVOD subjects because it is
considered a high-risk procedure in severe PH, one has to rely on clinical features
and non-invasive examinations outlined in the algorithm for PVOD management
of the French Reference Center for Pulmonary Hypertension[8]. In this respect,
sputum analysis for haemosiderin-laden macrophages might represent an asset in
the diagnostic puzzle. Using a crude Bayesian approach without consideration of
dependency of the variables, the likelihood ratios (LHR) of the single parameters
can be calculated. For instance, according to the data of Montani and colleagues,
the presence of septal lines in a chest computed tomography has a positive
(LHR+) and a negative LHR (LHR-) of 4.3 and 0.41, respectively. Due to our data,
the LHR+ and LHR- with respect to the presence of a Golde score .200 are 30.00
and 0.00, respectively. Hence, if both parameters would turn to be positive, by
multiplying the ratios, the post-test detection rate for a PVOD would be around
129:1. Hence, this study clearly shows that collection of sputum for the analysis of
haemosiderin-laden macrophages could be used as an important tool in the
diagnostic work-up of PVOD.
Of course, the current case series has its limitations. First, due to the fact that
PVOD is a very rare variant of an orphan disease with a prevalence of only 15
patients per one million habitants [18], the number of included patients is low
(n56). Nevertheless, this has to been put into the context that up to the year 2006,
only about 200 cases of PVOD have been reported in the literature. Secondly, a
histological confirmation was not obtained from all PVOD patients because lung
biopsy is not recommended in these patients [20]. Notwithstanding, one patient
of the current series underwent lung transplantation, and the Golde score in the
tissue was comparable to that found in the sputum. In an other cased, the Golde
score from the sputum was comparable to that of the BAL. Thirdly, even due to
the fact that sensitivity of the sputum examination for haemosiderin-laden
Haemosiderin-Laden Macrophages Are Increased in PVOD
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macrophages was statistically 100%, we would like to point out that the diagnostic
work-up can further be increased by a proper and repeated sputum collection.
In summary, the present study on patients suffering from PVOD indicates that
the collection of non-induced sputum for the analysis of haemosiderin-laden
macrophages could be used as a non-invasive diagnostic tool for the work-up of
PVOD.
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